CD8A and neoplasm: cDC1s also express CXC-chemokine ligand 9(CXCL9) and CXCL10 to activate CXCR3+ T and NK cells, recruit CD8+ T cells into the tumor sites, and foster the efficacy of anti-PD-1 or anti-TIM-3 therapy (de Mingo Pulido et al., 2018; Chow et al., 2019).